Key result
The newly developed NASBA assay detected group B and group A rhinoviruses with sensitivities of 20 and 200 TCID50, respectively, without amplifying RNA from other respiratory viruses.
The newly developed NASBA assay provides a sensitive and specific method for detecting and differentiating group A and B rhinoviruses.
NASBA enables specific rhinovirus detection; leaves open clinical diagnostic adoption pending prospective validation.
The isothermal nucleic acid sequence-based amplification (NASBA) system was applied for the detection of rhinoviruses using primers targeted at the 5' noncoding region (5' NCR) of the viral genome. The nucleotide sequence of the 5' NCRs of 34 rhinovirus isolates was determined to map the most conserved regions and design more appropriate primers and probes. The assay amplified RNA extracted from 30 rhinovirus reference strains and 88 rhinovirus isolates, it did not amplify RNA from 49 enterovirus isolates and other respiratory viruses. The assay allows one to discriminate between group A and B rhinoviruses. Sensitivities for the detection of group B and group A rhinoviruses was 20 and 200 50% tissue culture infective doses, respectively.
No takes yet. Share an insight, caveat, or question.
Loens et al. (2003) studied Rhinovirus infection (n=118). Nucleic acid sequence-based amplification (NASBA) assay was evaluated on Sensitivity for the detection of group B and group A rhinoviruses. The newly developed NASBA assay detected group B and group A rhinoviruses with sensitivities of 20 and 200 TCID50, respectively, without amplifying RNA from other respiratory viruses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: